Company intelligence / Profile preview
Dren Bio
Foster City, California, United Statesdrenbio.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Dren Bio’s lead clinical programs are:
- DR‑01, a first-in-class antibody for selective depletion of pathogenic CD8 T cells, currently in clinical evaluation for hematologic cancers and expanding into autoimmune indications.
- DR‑0201, a bispecific antibody targeting CD20 for deep B-cell depletion via myeloid cell engagement. Early clinical data show robust B-cell depletion with potential to reset the immune system. This program was acquired by Sanofi in March 2025 after promising early results.[4] The company also has multiple preclinical programs leveraging its proprietary platform across oncology, immunology, and neurology.[5]
- Therapeutic areas
- OncologyImmunology
- Modalities
- bispecific antibodiesmonoclonal antibodies (mAbs)protein engineering
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Novartis Pharma AG – strategic collaboration on bispecific antibodies for cancer announced July 2024Sanofi – acquisition of DR–0201 program/affiliate March–Q2’25
Beyond the preview
Go deeper on Dren Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dren Bio.